New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
15:30 EDTNXPI, WFT, SKX, ETFC, TSCO, CTXS, TRIP, ORLY, AVB, ILMN, CCI, GILD, QCOM, FB, TNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include AT&T (T), consensus 63c; Facebook (FB), consensus 32c; QUALCOMM (QCOM), consensus $1.22; Gilead (GILD), consensus $1.79; Crown Castle (CCI), consensus $1.01; Illumina (ILMN), consensus 51c; Avalonbay (AVB), consensus $1.66; O'Reilly Automotive (ORLY), consensus $1.85; TripAdvisor (TRIP), consensus 61c; Citrix (CTXS), consensus 61c; Tractor Supply (TSCO), consensus 95c; E*TRADE (ETFC), consensus 23c; Skechers (SKX), consensus 40c; Weatherford International (WFT), consensus 21c; NXP Semiconductors (NXPI), consensus $1.06
News For T;FB;QCOM;GILD;CCI;ILMN;AVB;ORLY;TRIP;CTXS;TSCO;ETFC;SKX;WFT;NXPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
September 18, 2014
12:12 EDTGILDStocks with call strike movement; PIR GILD
Subscribe for More Information
12:07 EDTFBStocks with call strike movement; JCP FB
Subscribe for More Information
10:34 EDTORLYHigh option volume stocks
Subscribe for More Information
09:34 EDTTAT&T extends NetBond security services to IBM SoftLayer platform
Subscribe for More Information
09:22 EDTSKXBack to school season healthy for footwear, says Sterne Agee
Subscribe for More Information
08:17 EDTGILDGilead trial failure not material, says FBR Capital
Subscribe for More Information
07:26 EDTQCOMGartner: Smartwatch market ready to expand, poised for takeoff, DigiTimes says
Subscribe for More Information
07:06 EDTFBFacebook volatility low into Alibaba IPO
Subscribe for More Information
September 17, 2014
15:06 EDTTAT&T met with Mexican telecommunications regulators, Bloomberg says
Subscribe for More Information
13:34 EDTTAT&T could need significant debt to pursue America Movil assets, WSJ says
Subscribe for More Information
12:46 EDTSKXSkechers pullback a buying opportunity, says Wunderlich
Subscribe for More Information
12:43 EDTSKXSkechers reiterated Buy at Wunderlich
Subscribe for More Information
11:52 EDTGILDStocks with call strike movement; X GILD
Subscribe for More Information
11:39 EDTTVerizon says tower sales options more favorable in current market
Subscribe for More Information
11:16 EDTSKXOptions with increasing implied volatility:
Options with increasing implied volatility: WB SDRL TAP AGNC IYR SKX
10:04 EDTFBDiscover rumored to be eyed as target by Apple, Bank Innovation says
Subscribe for More Information
09:40 EDTFBFacebook polishing micro-sharing app 'Moments', TechCrunch reports
Facebook is polishing a new app codenamed "Moments" for micro-sharing for a select group of friends, reports TechCrunch. According to multiple sources, including who has seen a live internal version of the app, the design features a grid with a few tiles, each representing a set of close family or friends. The goal is to make selective sharing much faster than the main Facebook app. Reference Link
09:01 EDTSKXSkechers files infringement lawsuit against DB Shoe Company
Subscribe for More Information
06:19 EDTQCOMGoogle picks former Qualcomm exec to head Google Fiber, WSJ reports
Google (GOOG) has hired Dennis Kish, a former Qualcomm (QCOM) executive, to head Google Fiber, replacing Milo Medin, the Wall Street Journal reports. A Google spokeswoman confirms that Medin remains a VP for access services and adviser to the Google Fiber team. Reference Link
06:04 EDTGILDGilead's simtuzumab Phase 2 study for pancreatic cancer does not meet endpoint
Gilead announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2, in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, the addition of simtuzumab to gemcitabine did not significantly increase progression-free survival compared to placebo plus gemcitabine. There was no difference in adverse events between patients taking simtuzumab versus placebo. Simtuzumab is being evaluated in several ongoing Phase 2 trials, including for advanced colorectal cancer, myelofibrosis, as monotherapy for idiopathic pulmonary fibrosis, and for liver fibrosis. Other agents in Gileadís oncology pipeline are currently being evaluated in clinical trials for the treatment of pancreatic cancer.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use